Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation
- Radboud Univ., Nijmegen (Netherlands). Radboud Inst. for Molecular Life Sciences. Faculty of Science. Dept. of Molecular Biology
- Wellcome Trust Sange Inst., Cambridge (United Kingdom); Univ. of Cambridge (United Kingdom). Academic Dept. of Medical Genetics
- Erasmus Univ. Medical Center, Rotterdam (Netherlands). Erasmus MC Cancer Inst. and Cancer Genomics Netherlands
- Wellcome Trust Sange Inst., Cambridge (United Kingdom); Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics; Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Center for Nonlinear Studies
- Wellcome Trust Sange Inst., Cambridge (United Kingdom)
- Lund Univ. (Sweden). Dept. of Clinical Sciences Lund. Division of Oncology and Pathology
- Centre Léon Bérard, Lyon (France). Synergie Lyon Cancer
- Wellcome Trust Genome Campus, Hinxton (United Kingdom). European Bioinformatics Inst. European Molecular Biology Lab.
- The Norwegian Radium Hospital (Norway). Oslo Univ. Hospital. Inst. for Cancer Research. Dept. of Genetics
- The Norwegian Radium Hospital (Norway). Oslo Univ. Hospital. Inst. for Cancer Research. Dept. of Genetics; Univ. of Oslo (Norway). Inst. for Clinical medicine. K.G. Jebsen Centre for Breast Cancer Research; Akerhus Univ. Hospital, Lørenskog (Norway). Division of Medicine. Dept. of Clinical moelcular Biology and Lab. Science (EpiGen)
- Parc Cientific de Barcelona (Spain). Centro nacional de Análisis Genómico (CNAG)
- Academic Medical Center, Amsterdam (Netherlands). Dept. of Pathology
- The Norwegian Radium Hospital (Norway). Oslo Univ. Hospital. Inst. for Cancer Research. Dept. of Genetics; Univ. of Oslo (Norway). Inst. for Clinical medicine. K.G. Jebsen Centre for Breast Cancer Research
- Brigham and Women's Hospital (Harvard Medical School), Boston, MA (United States). Dept. of Pathology; Dana-Farber Cancer Institute, Boston, MA (United States)
Global loss of DNA methylation and CpG island (CGI) hypermethylation are key epigenomic aberrations in cancer. Global loss manifests itself in partially methylated domains (PMDs) which extend up to megabases. However, the distribution of PMDs within and between tumor types, and their effects on key functional genomic elements including CGIs are poorly defined. We comprehensively show that loss of methylation in PMDs occurs in a large fraction of the genome and represents the prime source of DNA methylation variation. PMDs are hypervariable in methylation level, size and distribution, and display elevated mutation rates. They impose intermediate DNA methylation levels incognizant of functional genomic elements including CGIs, underpinning a CGI methylator phenotype (CIMP). Repression effects on tumor suppressor genes are negligible as they are generally excluded from PMDs. The genomic distribution of PMDs reports tissue-of-origin and may represent tissue-specific silent regions which tolerate instability at the epigenetic, transcriptomic and genetic level.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC)
- Grant/Contract Number:
- AC52-06NA25396
- OSTI ID:
- 1624152
- Journal Information:
- Nature Communications, Vol. 10, Issue 1; ISSN 2041-1723
- Publisher:
- Nature Publishing GroupCopyright Statement
- Country of Publication:
- United States
- Language:
- English
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
|
journal | September 2019 |
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
|
journal | December 2019 |
Random forest-based modelling to detect biomarkers for prostate cancer progression
|
journal | October 2019 |
Determining subpopulation methylation profiles from bisulfite sequencing data of heterogeneous samples using DXM
|
journal | June 2021 |
Similar Records
Impriniting of human H19: Allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching
DNA methylation analysis using CpG microarrays is impaired in benzopyrene exposed cells